Abstract
Gold nanoparticle (AuNP) radiosensitization represents a novel approach to enhance the effectiveness of ionizing radiation. Its efficiency varies widely with photon source energy and AuNP size, concentration, and intracellular localization. In this Monte Carlo study we explored the effects of those parameters to define the optimal clinical use of AuNPs. Photon sources included 103Pd and 125I brachytherapy seeds; 169Yb, 192Ir high dose rate sources, and external beam sources 300 kVp and 6 MV. AuNP sizes were 1.9, 5, 30, and 100 nm. We observed a 103 increase in the rate of photoelectric absorption using 125I compared to 6 MV. For a 125I source, to double the dose requires concentrations of 5.33–6.26 mg g−1 of Au or 7.10 × 104 30 nm AuNPs per tumor cell. For 6 MV, concentrations of 1560–1760 mg g−1 or 2.17 × 107 30 nm AuNPs per cell are needed, which is not clinically achievable. Examining the proportion of energy transferred to escaping particles or internally absorbed in the nanoparticle suggests two clinical strategies: the first uses photon energies below the k-edge and takes advantage of the extremely localized Auger cascade. It requires small AuNPs conjugated to tumor targeted moieties and nuclear localizing sequences. The second, using photon sources above the k-edge, requires a higher gold concentration in the tumor region. In this approach, energy deposited by photoelectrons is the main contribution to radiosensitization; AuNP size and cellular localization are less relevant.
Export citation and abstract BibTeX RIS
General scientific summary. Gold nanoparticles (AuNPs) are currently being investigated to enhance the biological effect of radiation treatment at the tumor site. It has been shown that this radiobiological enhancement varies widely with a number of physics and pharmacological parameters including irradiation energy and AuNP size, concentration and intracellular localization. In this study, we simulated the effects of those parameters to define the optimal use of AuNPs as part of a clinical strategy. One scenario involves low energy photon sources such as 125I brachytherapy seeds along with small AuNPs localized within 2 microns of the cell nucleus with concentrations of 5.39 mg of AuNPs per g of tumor. Another scenario involves higher energy sources requiring concentrations of 12.1–13.7 mg AuNP per g for the 169Yb HDR source and 15.4–20.2 mg AuNP per g for the 300 kVp source. Under these conditions a dose enhancement of at least 2 is predicted.
For more information on this article, see medicalphysicsweb.org